Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $10.86 in the prior trading day, Cogent Biosciences Inc (NASDAQ: COGT) closed at $10.96, up 0.92%. In other words, the price has increased by $0.92 from its previous closing price. On the day, 1.33 million shares were traded. COGT stock price reached its highest trading level at $11.2391 during the session, while it also had its lowest trading level at $10.7.
Ratios:
Our goal is to gain a better understanding of COGT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.19 and its Current Ratio is at 4.19. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $17.
Robert W. Baird Downgraded its Outperform to Neutral on February 26, 2024, whereas the target price for the stock was revised from $14 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 10 ’25 when Fairmount Funds Management LLC bought 2,777,777 shares for $9.00 per share. The transaction valued at 24,999,993 led to the insider holds 9,003,418 shares of the business.
Pinnow Cole bought 43,750 shares of COGT for $332,412 on Jan 14 ’25. The Chief Commercial Officer now owns 45,848 shares after completing the transaction at $7.60 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COGT now has a Market Capitalization of 1531122816 and an Enterprise Value of 1462659840.
Stock Price History:
The Beta on a monthly basis for COGT is 0.35, which has changed by 0.28941178 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, COGT has reached a high of $12.97, while it has fallen to a 52-week low of $3.72. The 50-Day Moving Average of the stock is 19.65%, while the 200-Day Moving Average is calculated to be 36.59%.
Shares Statistics:
The stock has traded on average 2.85M shares per day over the past 3-months and 1685360 shares per day over the last 10 days, according to various share statistics. A total of 139.70M shares are outstanding, with a floating share count of 117.32M. Insiders hold about 16.02% of the company’s shares, while institutions hold 84.64% stake in the company. Shares short for COGT as of 1752537600 were 13759795 with a Short Ratio of 4.83, compared to 1749772800 on 16522675. Therefore, it implies a Short% of Shares Outstanding of 13759795 and a Short% of Float of 11.21.
Earnings Estimates
The current rating of Cogent Biosciences Inc (COGT) reflects the combined expertise of 11.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.37 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$1.85 and -$2.41 for the fiscal current year, implying an average EPS of -$2.15. EPS for the following year is -$1.79, with 11.0 analysts recommending between -$0.98 and -$2.41.
